Upadacitinib Clinical Trials

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

103

Total Trials

Recruiting

Completed

36,069

Total Enrollment

States

Upadacitinib Evidence & Publications

191 peer-reviewed publications + per-arm primary-outcome data from 42 pivotal trials.

See published evidence →

Upadacitinib Clinical Trials

Sortable list of all 103 Upadacitinib trials — recruiting status, pivotal acronyms, indication grouping, NCT links.

See all trials →

Upadacitinib History and Updates

Every FDA approval, label revision, recall, trial milestone, and pivotal publication for Upadacitinib — sourced from openFDA, ClinicalTrials.gov, and PubMed.

See full history →

Recent Upadacitinib updates

See full history →

Upadacitinib Phase 3 Trial for Atopic Dermatitis Sleep Disturbance Withdrawn· Jan 5, 2026
Rinvoq (Upadacitinib) Receives FDA Supplemental Approval for Efficacy· Oct 10, 2025
Upadacitinib Phase 3 Vitiligo Trial Reaches Primary Completion· Sep 23, 2025
Upadacitinib Atopic Dermatitis Trial Shows EASI 90/75/100 Scores at Week 24· Jul 29, 2025
Rinvoq (Upadacitinib) Receives FDA Supplemental Approval for Efficacy· Apr 28, 2025
Upadacitinib Shows Improved Remission, Reduced Corticosteroid Use in Giant…· Mar 7, 2025
Upadacitinib Shows Superior Efficacy vs. Dupilumab in Atopic Dermatitis Trial· Feb 14, 2025
Upadacitinib Phase 3 Trial Results Published for Giant-Cell Arteritis· Jan 1, 2025

What Is Upadacitinib?

Upadacitinib is an FDA-approved medication for certain inflammatory conditions, including **rheumatoid arthritis**, **atopic dermatitis**, and **ulcerative colitis**. It is an oral selective **Janus kinase 1 (JAK1) inhibitor**. This means it works by blocking the activity of the JAK1 enzyme, which plays a key role in the inflammatory pathways of the immune system. By inhibiting JAK1, upadacitinib helps to reduce inflammation and manage symptoms associated with various autoimmune and inflammatory diseases.

In addition to its approved uses, upadacitinib is being investigated for other conditions such as Crohn's disease, psoriatic arthritis, alopecia areata, vitiligo, hidradenitis suppurativa, and systemic lupus erythematosus.

Uses and Conditions Under Study

Upadacitinib is being studied across a wide range of inflammatory and autoimmune conditions, with a total of **103 trials** involving **36,069 participants**. The first trial began in 2014, and the latest is projected to conclude in 2026. A significant portion of these trials, **33**, are currently recruiting new participants, while **38** have been completed.

Skin Conditions: Upadacitinib is extensively studied for skin conditions. For **atopic dermatitis** (eczema), which causes rash and itching due to skin inflammation, there are **19 trials**. Studies assess its efficacy and safety, including comparisons to other treatments like dupilumab, and its impact on sleep disturbances. For **alopecia areata**, a disease where the immune system attacks hair follicles leading to hair loss, **3 trials** are assessing its safety and effectiveness in adolescents and adults. **Vitiligo**, a chronic autoimmune disease causing pigment loss, is being investigated in **2 trials**. Additionally, **hidradenitis suppurativa**, an inflammatory skin disease causing painful lesions, is under study, as is **lichen planus**, a common immune-mediated skin disease.
Inflammatory Bowel Diseases (IBD): Upadacitinib is a focus for IBD, which includes ulcerative colitis and Crohn's disease. For **ulcerative colitis (UC)**, a condition causing inflammation and bleeding in the colon, there are **7 trials** (plus **3 trials** specifically for acute severe ulcerative colitis and another **3 trials** for general ulcerative colitis). For **Crohn's disease (CD)**, a chronic inflammatory disorder of the digestive tract, there are **6 trials**. These studies aim to assess upadacitinib's effectiveness in reducing inflammation and improving symptoms, including anal fistula in Crohn's disease.
Rheumatic Conditions: For **rheumatoid arthritis (RA)**, a chronic inflammatory disease causing joint pain, stiffness, and swelling, there are **13 trials** (plus another **4 trials** specifically for RA). Upadacitinib is being compared to other treatments like adalimumab. **Psoriatic arthritis**, which affects people with psoriasis and causes joint inflammation, is being investigated in **5 trials**. **Systemic lupus erythematosus (SLE)**, an immune-mediated disease affecting multiple organ systems, is also under study.
Other Conditions: Upadacitinib is also being explored for its potential in **Long Covid**, a condition characterized by persistent symptoms after COVID-19 infection.

Dosing

Upadacitinib is primarily available as **oral tablets**, including extended-release formulations. The specific dosage and frequency depend on the condition being treated and are determined by clinical trials and physician guidance.

For adults, common strengths studied include **15 mg**, **30 mg**, and **45 mg** taken once daily. For example, in studies for acute severe ulcerative colitis, participants have received upadacitinib **45 mg** orally once daily during hospitalization, sometimes followed by a transition to **30 mg** once daily after discharge. For other conditions like rheumatoid arthritis or atopic dermatitis, doses such as **15 mg** or **30 mg** once daily have been investigated.

Pediatric studies are also exploring upadacitinib for conditions such as atopic dermatitis, ulcerative colitis, and alopecia areata. These trials involve various age groups, including participants from **2 to less than 18 years** old, to assess appropriate dosing and safety profiles for younger patients.

Side Effects

In clinical trials, the most common side effect reported by patients taking Upadacitinib was upper respiratory tract infection. This occurred in 8.6% of patients on Upadacitinib, compared to 5.3% of patients on placebo. Other frequently observed side effects included:

Acne: 7.8% of patients taking Upadacitinib experienced acne, compared to 2.2% on placebo.
Nasopharyngitis: 7.7% of patients taking Upadacitinib experienced nasopharyngitis, compared to 4.9% on placebo.
Increased blood creatine phosphokinase: 6.9% of patients taking Upadacitinib had elevated levels, compared to 3.5% on placebo.
Increased alanine aminotransferase: 6.6% of patients taking Upadacitinib had elevated levels, compared to 3.2% on placebo.
Urinary tract infection: 5.6% of patients taking Upadacitinib experienced urinary tract infection, compared to 4.1% on placebo.
Hypertension (high blood pressure): 5.5% of patients taking Upadacitinib experienced hypertension, compared to 3.7% on placebo.
Headache: 5.1% of patients taking Upadacitinib experienced headache, compared to 3.9% on placebo.

Clinical Trial Results

Upadacitinib in Rheumatoid Arthritis

An open-label extension study (NCT02049138) evaluated the long-term safety and effectiveness of Upadacitinib in adults with rheumatoid arthritis. Patients who received Upadacitinib without dose adjustments showed an average improvement in their Clinical Disease Activity Index (CDAI) score of approximately -35 points from baseline. The Disease Activity Score based on CRP (DAS28[CRP]) also improved, with an average reduction of about -3.5 points. Furthermore, between 23% and 53% of patients achieved clinical remission based on CDAI, and 87% to 96% achieved at least a 20% improvement in ACR criteria (ACR20 response) over time.

In a study () compared Upadacitinib to placebo and adalimumab in adults with rheumatoid arthritis who had an inadequate response to methotrexate. At Week 12, patients on Upadacitinib experienced an average reduction in DAS28 (CRP) of -2.48 units, which was greater than the -1.15 units seen with placebo and -2.01 units with adalimumab. An ACR20 response was achieved by 70.5% of patients on Upadacitinib, compared to 36.4% on placebo and 63.0% on adalimumab. Additionally, 45.2% of Upadacitinib patients achieved an ACR50 response (vs. 14.9% placebo, 29.1% adalimumab), and 24.9% achieved an ACR70 response (vs. 4.9% placebo, 13.5% adalimumab). Upadacitinib also showed a lower mean change in Modified Total Sharp Score (mTSS) at Week 26 (0.24 units), indicating less radiographic progression compared to placebo (0.92 units).

In a study () in rheumatoid arthritis patients with inadequate response or intolerance to biologic DMARDs showed that at Week 12, Upadacitinib 15 mg resulted in an ACR20 response in 64.6% of patients, compared to 28.4% on placebo. ACR50 was achieved by 34.1% of Upadacitinib 15 mg patients (vs. 11.8% placebo), and ACR70 by 11.6% (vs. 6.5% placebo). The mean reduction in DAS28 (CRP) was -2.31 units for Upadacitinib 15 mg, compared to -1.02 units for placebo.

Currently Recruiting Trials

Researchers are actively recruiting participants for numerous clinical trials involving upadacitinib, exploring its potential across a range of inflammatory conditions. These studies aim to further understand its effectiveness and safety, sometimes comparing it to existing treatments or investigating new combinations. For patients with acute severe ulcerative colitis, several Phase 4 trials are underway. The UPRISE study, NCT07550673, is comparing upadacitinib against infliximab as a second-line treatment, aiming to enroll 226 participants. Another study, NCT07546097 (UPFRONT), is evaluating upadacitinib versus corticosteroids as a first-line therapy, with a target of 46 participants. A third Phase 4 trial, NCT07258771, is investigating upadacitinib combined with corticosteroids versus corticosteroid monotherapy for both inpatients and outpatients, seeking 110 participants. McMaster University is sponsoring NCT06660693, a Phase 3 study comparing upadacitinib to infliximab as rescue strategies for steroid-refractory acute severe ulcerative colitis, with an enrollment goal of 134 individuals. Additionally, NCT05867329 is a Phase 4 feasibility pilot study exploring personalized treatment sequences for acute severe ulcerative colitis, planning for 162 participants. A real-world effectiveness study, NCT07442045, is also evaluating upadacitinib alone or combined with vedolizumab in moderate-to-severe ulcerative colitis, with 150 participants. In Crohn's disease, NCT07510191 is a Phase 4 trial comparing standard-dose TNFi plus low-dose upadacitinib to TNFi dose intensification for patients with suboptimal response, targeting 312 participants. Takeda is sponsoring a Phase 3 study, NCT06227910, assessing vedolizumab with and without upadacitinib in adults with Crohn's disease, aiming for 396 participants. For pediatric patients, AbbVie is conducting a Phase 3 study, NCT06332534, to evaluate the efficacy, safety, and pharmacokinetics of upadacitinib in 110 children and adolescents with moderately to severely active Crohn's disease. Another Phase 4 trial, NCT06520397, is comparing dual-targeted therapy with upadacitinib and ustekinumab versus intensified ustekinumab monotherapy in Crohn's disease, with 214 participants. A Phase 1 study, NCT06902987, is also investigating upadacitinib for active anal fistulas in Crohn's disease, with 27 participants. For alopecia areata, AbbVie is sponsoring two large Phase 3 trials: NCT07023302, enrolling 123 adult and adolescent participants in Japan, and NCT06012240, a global study targeting 1500 participants with severe alopecia areata. Another study, NCT06573593, is collecting real-world evidence on the efficacy and safety of JAK inhibitors, including upadacitinib, for alopecia areata, with 150 participants. In atopic dermatitis, AbbVie has initiated a Phase 3 study, NCT06461897, comparing upadacitinib to dupilumab in 675 children aged 2 to less than 12 years with moderate to severe atopic dermatitis. Another AbbVie Phase 3 trial, NCT06389136, is studying upadacitinib in 200 adult participants with moderate-to-severe atopic dermatitis who had an inadequate response to dupilumab. Other conditions being studied include:

Long COVID: The LC-REVITALIZE study, NCT06928272, is a Phase 3 trial testing repurposed drugs, including upadacitinib, for Long COVID symptoms, aiming for 348 participants.
Psoriatic Arthritis: NCT06454188 is a Phase 4 study evaluating the impact of upadacitinib on spondyloarthritis outcomes in 100 patients with active psoriatic arthritis.
Relapsing Polychondritis: Peking University People's Hospital is sponsoring a Phase 1/Phase 2 study, NCT06873100, to assess the efficacy and safety of upadacitinib in 30 participants.
Juvenile Idiopathic Arthritis: AbbVie is conducting a Phase 3 study, NCT05609630, to evaluate upadacitinib and tocilizumab in 90 pediatric and adolescent participants with active systemic juvenile idiopathic arthritis.
Hidradenitis Suppurativa: A large Phase 3 study, NCT05889182, is assessing upadacitinib in 1328 adult and adolescent participants with moderate to severe hidradenitis suppurativa who have failed anti-TNF therapy.
Prurigo Nodularis: NCT06773403 is a Phase 4 open-label study of upadacitinib in 25 patients with moderate-to-severe prurigo nodularis.
Vitiligo: NCT06454461 is investigating the efficacy of upadacitinib after NECS in 60 participants with vitiligo.
Healthy Volunteers: A Phase 1 study, NCT07425899, is investigating the safety and pharmacokinetics of ABBV-722 and upadacitinib in 32 healthy adult participants.
Pharmacokinetics: NCT06379958 is a Phase 1 drug-drug interaction study of leramistat, including a part with upadacitinib, in 48 healthy adult subjects.

Several other studies are also recruiting for inflammatory bowel disease, axial spondyloarthritis, and real-world safety monitoring.

Where to Participate

Clinical trials for upadacitinib are currently active across 39 states and 162 cities, with 316 sites participating globally. The top locations for these studies in the United States include:

New York, New York (13 sites)
Tampa, Florida (8 sites)
Dallas, Texas (8 sites)
Portland, Oregon (7 sites)
Chicago, Illinois (6 sites)
Indianapolis, Indiana (6 sites)
Boston, Massachusetts (6 sites)
Sacramento, California (6 sites)
Philadelphia, Pennsylvania (5 sites)
Miami, Florida (5 sites)

Eligibility for these trials generally ranges from 1 to 85 years of age, and all genders are welcome to participate. Many studies are specifically designed for patients with certain conditions, but some trials also recruit healthy volunteers, and children are eligible for several studies.

Development Timeline

The development journey for upadacitinib began with its first clinical trial on January 30, 2014. Since then, a robust research program has unfolded, encompassing a total of 103 trials with an impressive cumulative enrollment of 36,069 participants. AbbVie has been the primary driver of this research, sponsoring 56 of these trials, leading the charge in exploring the drug's potential. Initially, upadacitinib's pipeline focused on conditions such as IBS-C and hyperphosphatemia. However, its development quickly expanded to target a broader spectrum of inflammatory and autoimmune diseases. Key milestones include significant research into Ulcerative Colitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, and Alopecia Areata. The drug's journey has progressed through various phases, with 45 trials reaching Phase 3, indicating advanced stages of investigation, and 15 trials in Phase 4, which often involves post-market surveillance and comparative effectiveness studies. The latest trial is projected to conclude on April 24, 2026, underscoring ongoing commitment to understanding upadacitinib's full therapeutic potential. This expansion reflects a strategic effort to address unmet needs across a wide range of conditions where inflammation plays a central role.

Upadacitinib Development Timeline

Clinical trial activity from 2014 to 2026.

2026

NCT07352566PHASE4not yet recruiting

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

10 enrolled

NCT07502339PHASE4not yet recruiting

Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis

50 enrolled

NCT07492251PHASE2not yet recruiting

Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.

56 enrolled

NCT07018206PHASE4not yet recruiting

Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis

200 enrolled

NCT07448363not yet recruiting

Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica

50 enrolled

NCT06016517not yet recruiting

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

18 enrolled

NCT07550673PHASE4recruiting

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

226 enrolled

NCT07546097PHASE4recruiting

Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）

46 enrolled

NCT07510191PHASE4recruiting

TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response

312 enrolled

NCT07425899PHASE1recruiting

A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants

32 enrolled

NCT07258771PHASE4recruiting

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

110 enrolled

NCT07487311recruiting

A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)

80 enrolled

2025

NCT06684522EARLY_PHASE1recruiting

Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

10 enrolled

NCT07138898PHASE2not yet recruiting

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

80 enrolled

NCT06928272PHASE3recruiting

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

348 enrolled

NCT07149467PHASE3not yet recruiting

Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study

454 enrolled

NCT07064889PHASE2not yet recruiting

The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

132 enrolled

NCT07023302PHASE3recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

123 enrolled

NCT07008846PHASE3active not recruiting

Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis

96 enrolled

NCT06660693PHASE3recruiting

Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis

134 enrolled

NCT06862284PHASE2not yet recruiting

Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

30 enrolled

NCT06227910PHASE3recruiting

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

396 enrolled

NCT06687551PHASE4not yet recruiting

JAK Inhibitor Dose TAPering Strategy Study

308 enrolled

2024

NCT06701331PHASE3active not recruiting

Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis

99 enrolled

NCT06454461NArecruiting

Efficacy of Upadacitinib After NECS in Vitiligo

60 enrolled

NCT06454188PHASE4recruiting

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

100 enrolled

NCT06873100PHASE1/PHASE2recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

30 enrolled

NCT06461897PHASE3recruiting

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

675 enrolled

NCT06332534PHASE3recruiting

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

110 enrolled

NCT06573593recruiting

Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study

150 enrolled

NCT06630715recruiting

Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.

178 enrolled

NCT06520397PHASE4recruiting

Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease

214 enrolled

NCT06498167recruiting

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

150 enrolled

NCT06389136PHASE3recruiting

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

200 enrolled

NCT06390722PHASE3withdrawn

A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

0 enrolled

NCT06773403PHASE4terminated

Upadacitinib for Prurigo Nodularis

5 enrolled

NCT06379958PHASE1recruiting

Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects

48 enrolled

NCT07080346PHASE2completed

Upadacitinib for Refractory Behcet's Syndrome

27 enrolled

NCT06902987PHASE1recruiting

Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease

27 enrolled

NCT06780683recruiting

Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease

174 enrolled

2023

NCT06144567not yet recruiting

Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis

19 enrolled

NCT06118411PHASE3active not recruiting

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

614 enrolled

NCT05782907PHASE3active not recruiting

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

122 enrolled

NCT06095596NArecruiting

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

334 enrolled

NCT06012240PHASE3recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

1,500 enrolled

NCT05609630PHASE3recruiting

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

90 enrolled

NCT05867329PHASE4recruiting

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

162 enrolled

NCT05843643PHASE3active not recruiting

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

1,014 enrolled

NCT05889182PHASE3recruiting

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

1,328 enrolled

NCT05814627PHASE3active not recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

487 enrolled

NCT07472309completed

Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis

81 enrolled

NCT05507580PHASE4completed

A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

461 enrolled

NCT06758947PHASE3completed

Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF

60 enrolled

NCT07442045recruiting

Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis

150 enrolled

NCT06922331completed

Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis

21 enrolled

2022

NCT05601882PHASE3completed

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

920 enrolled

NCT05153200PHASE4unknown

Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.

40 enrolled

2021

NCT05094128active not recruiting

A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting

338 enrolled

NCT05080218PHASE4completed

COVID-19 VaccinE Response in Rheumatology Patients

841 enrolled

NCT06937788recruiting

Replication of the Heads Up Atopic Dermatitis Trial With Registry Data

240 enrolled

NCT04927975PHASE2completed

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

185 enrolled

NCT05121298PHASE3unknown

Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate

155 enrolled

NCT04530305unknown

Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor

60 enrolled

NCT06274996completed

Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease

81 enrolled

2020

NCT04666675PHASE3withdrawn

A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil

0 enrolled

NCT04451772PHASE2completed

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

185 enrolled

NCT04430855PHASE2completed

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

68 enrolled

NCT04161898PHASE3active not recruiting

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

56 enrolled

NCT04195698PHASE3completed

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

475 enrolled

2019

NCT04169373PHASE3completed

A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

734 enrolled

NCT04159597available

Expanded Access to Upadacitinib

0 enrolled

NCT03978520PHASE2completed

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

341 enrolled

NCT03725007PHASE1active not recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

124 enrolled

NCT03823378PHASE2terminated

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

97 enrolled

NCT03738397PHASE3completed

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

673 enrolled

NCT03646604PHASE1completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

35 enrolled

NCT03725202PHASE3completed

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

429 enrolled

2018

NCT03653026PHASE3completed

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

522 enrolled

NCT03661138PHASE3completed

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

272 enrolled

NCT03682705PHASE2completed

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

242 enrolled

NCT03569293PHASE3completed

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

912 enrolled

NCT03568318PHASE3active not recruiting

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

1,533 enrolled

NCT03607422PHASE3completed

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

912 enrolled

NCT03345823PHASE3active not recruiting

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

747 enrolled

NCT02955212PHASE3completed

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

338 enrolled

2017

NCT03345849PHASE3completed

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

526 enrolled

NCT03345836PHASE3completed

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

624 enrolled

NCT03178487PHASE2completed

A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis

187 enrolled

NCT03086343PHASE3completed

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

657 enrolled

NCT03104374PHASE3completed

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

642 enrolled

NCT03104400PHASE3completed

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

1,705 enrolled

NCT03006068PHASE3active not recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

950 enrolled

NCT03358693recruiting

Molecular Signatures in Inflammatory Skin Disease

300 enrolled

2016

NCT02925117PHASE2completed

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

167 enrolled

NCT02819635PHASE2/PHASE3completed

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

1,302 enrolled

NCT02706951PHASE3completed

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

648 enrolled

NCT02720523PHASE2/PHASE3completed

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs

197 enrolled

NCT02706847PHASE3completed

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

499 enrolled

NCT02706873PHASE3completed

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate

1,002 enrolled

2015

NCT02675426PHASE3completed

A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

661 enrolled

NCT02629159PHASE3active not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

1,629 enrolled

2014

NCT02066389PHASE2completed

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

300 enrolled

NCT02049138PHASE2completed

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis

493 enrolled

Conditions Under Study

Condition	NCT ID	Title	Status	Phase	Enrollment
Atopic Dermatitis	NCT07448363	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	not yet recruiting	N/A	50
	NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	not yet recruiting	PHASE4	10
	NCT06701331	Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis	active not recruiting	PHASE3	99
	NCT06461897	A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis	recruiting	PHASE3	675
	NCT06389136	A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab	recruiting	PHASE3	200
	NCT06390722	A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis	withdrawn	PHASE3	0
	NCT05507580	A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis	completed	PHASE4	461
	NCT05601882	A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	completed	PHASE3	920
	NCT06937788	Replication of the Heads Up Atopic Dermatitis Trial With Registry Data	recruiting	N/A	240
	NCT04195698	Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis	completed	PHASE3	475
	NCT03738397	A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis	completed	PHASE3	673
	NCT03646604	A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis	completed	PHASE1	35
	NCT03661138	A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	completed	PHASE3	272
	NCT03569293	Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)	completed	PHASE3	912
	NCT03568318	A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	active not recruiting	PHASE3	1,533
	NCT03607422	A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)	completed	PHASE3	912
	NCT03358693	Molecular Signatures in Inflammatory Skin Disease	recruiting	N/A	300
	NCT02925117	A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis	completed	PHASE2	167
	NCT04159597	Expanded Access to Upadacitinib	available	N/A	0
Rheumatoid Arthritis	NCT05814627	Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis	active not recruiting	PHASE3	487
	NCT05153200	Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.	unknown	PHASE4	40
	NCT05080218	COVID-19 VaccinE Response in Rheumatology Patients	completed	PHASE4	841
	NCT05121298	Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate	unknown	PHASE3	155
	NCT04530305	Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor	unknown	N/A	60
	NCT02706951	A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)	completed	PHASE3	648
	NCT02720523	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	completed	PHASE2/PHASE3	197
	NCT02706847	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs	completed	PHASE3	499
	NCT02706873	A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate	completed	PHASE3	1,002
	NCT02675426	A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone	completed	PHASE3	661
	NCT02629159	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate	active not recruiting	PHASE3	1,629
	NCT02066389	A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone	completed	PHASE2	300
	NCT02049138	An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis	completed	PHASE2	493
Ulcerative Colitis (UC)	NCT06095596	Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis	recruiting	NA	334
	NCT07472309	Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis	completed	N/A	81
	NCT07442045	Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis	recruiting	N/A	150
	NCT06922331	Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis	completed	N/A	21
	NCT03653026	A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis	completed	PHASE3	522
	NCT03006068	A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)	active not recruiting	PHASE3	950
	NCT02819635	A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)	completed	PHASE2/PHASE3	1,302
Crohn's Disease	NCT06227910	A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease	recruiting	PHASE3	396
	NCT06332534	Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease	recruiting	PHASE3	110
	NCT06780683	Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease	recruiting	N/A	174
	NCT03345823	A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433	active not recruiting	PHASE3	747
	NCT03345849	A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies	completed	PHASE3	526
	NCT03345836	A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy	completed	PHASE3	624
Psoriatic Arthritis	NCT06454188	A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis	recruiting	PHASE4	100
	NCT06144567	Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis	not yet recruiting	N/A	19
	NCT05080218	COVID-19 VaccinE Response in Rheumatology Patients	completed	PHASE4	841
	NCT03104374	A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug	completed	PHASE3	642
	NCT03104400	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)	completed	PHASE3	1,705
Rheumatoid Arthritis (RA)	NCT03823378	A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib	terminated	PHASE2	97
	NCT03682705	A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis	completed	PHASE2	242
	NCT02955212	A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)	completed	PHASE3	338
	NCT03086343	A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs	completed	PHASE3	657
Alopecia Areata	NCT07023302	A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata	recruiting	PHASE3	123
	NCT06573593	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	recruiting	N/A	150
	NCT06012240	A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata	recruiting	PHASE3	1,500
Ulcerative Colitis	NCT06780683	Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease	recruiting	N/A	174
	NCT05782907	Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.	active not recruiting	PHASE3	122
	NCT04159597	Expanded Access to Upadacitinib	available	N/A	0
Acute Severe Ulcerative Colitis	NCT07550673	Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）	recruiting	PHASE4	226
	NCT07546097	Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）	recruiting	PHASE4	46
	NCT07472309	Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis	completed	N/A	81
Vitiligo	NCT06454461	Efficacy of Upadacitinib After NECS in Vitiligo	recruiting	NA	60
	NCT06118411	A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo	active not recruiting	PHASE3	614
Psoriasis	NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	not yet recruiting	PHASE4	10
	NCT03358693	Molecular Signatures in Inflammatory Skin Disease	recruiting	N/A	300
Crohn Disease	NCT06520397	Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease	recruiting	PHASE4	214
	NCT04159597	Expanded Access to Upadacitinib	available	N/A	0
Atopic Dermatitis (AD)	NCT07448363	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	not yet recruiting	N/A	50
	NCT04666675	A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil	withdrawn	PHASE3	0
Systemic Lupus Erythematosus (SLE)	NCT04451772	A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State	completed	PHASE2	185
	NCT03978520	A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)	completed	PHASE2	341
Ulcerative Colitis Acute	NCT07258771	Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis	recruiting	PHASE4	110
	NCT05867329	Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis	recruiting	PHASE4	162
Upadacitinib	NCT06902987	Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease	recruiting	PHASE1	27
	NCT07472309	Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis	completed	N/A	81
Crohn's Disease Aggravated	NCT07149467	Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study	not yet recruiting	PHASE3	454
Crohn's Disease in Remission	NCT07149467	Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study	not yet recruiting	PHASE3	454
Crohn's Diseases	NCT06902987	Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease	recruiting	PHASE1	27
Drug Side Effect	NCT06498167	Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)	recruiting	N/A	150
Drug Use	NCT06498167	Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)	recruiting	N/A	150
Eyelid Dermatitis	NCT06684522	Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis	recruiting	EARLY_PHASE1	10
Geriatric Ulcerative Colitis	NCT06922331	Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis	completed	N/A	21
Giant Cell Arteritis (GCA)	NCT03725202	A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis	completed	PHASE3	429
Healthy Volunteer	NCT07425899	A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants	recruiting	PHASE1	32
Hidradenitis Suppurativa	NCT05889182	A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy	recruiting	PHASE3	1,328
Hidradenitis Suppurativa (HS)	NCT04430855	A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms	completed	PHASE2	68
Idiopathic Arthritis (Including sJIA, pJIA, or JPsA)	NCT04159597	Expanded Access to Upadacitinib	available	N/A	0
Immune Thrombocytopenia	NCT07064889	The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia	not yet recruiting	PHASE2	132
Inflamatory Bowel Disease	NCT07487311	A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)	recruiting	N/A	80
Inflammatory Bowel Disease	NCT06780683	Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease	recruiting	N/A	174
Inflammatory Bowel Disease (IBD)	NCT06922331	Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis	completed	N/A	21
Inflammatory Bowel Diseases	NCT06274996	Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease	completed	N/A	81
Inflammatory Disease	NCT06498167	Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)	recruiting	N/A	150
Interstitial Lung Disease Due to Systemic Disease (Disorder)	NCT06758947	Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	completed	PHASE3	60
JAK Inhibitor	NCT05121298	Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate	unknown	PHASE3	155
Janus Kinase Inhibitors	NCT06573593	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	recruiting	N/A	150
Juvenile Idiopathic Arthritis	NCT05609630	Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.	recruiting	PHASE3	90
Juvenile Idiopathic Arthritis (JIA)	NCT03725007	A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis	active not recruiting	PHASE1	124
Lichen Penis Planus	NCT07492251	Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.	not yet recruiting	PHASE2	56
Long COVID	NCT06928272	Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study	recruiting	PHASE3	348
Moderate to Severe Rheumatoid Arthritis	NCT07008846	Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis	active not recruiting	PHASE3	96
Musculoskeletal Ultrasound	NCT05121298	Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate	unknown	PHASE3	155
Non-Segmental Vitiligo	NCT04927975	Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo	completed	PHASE2	185
Pediatric Crohn's Disease	NCT06922331	Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis	completed	N/A	21
Pharmacokinetics	NCT06379958	Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects	recruiting	PHASE1	48
Primary Sjögren's Syndrome (pSS)	NCT06862284	Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome	not yet recruiting	PHASE2	30
Prurigo Nodularis	NCT06773403	Upadacitinib for Prurigo Nodularis	terminated	PHASE4	5
Psoriatic Arthritis (PsA	NCT06630715	Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.	recruiting	N/A	178
Refractory Crohn's Disease	NCT06922331	Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis	completed	N/A	21
Refractory Ulcerative Colitis	NCT06922331	Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis	completed	N/A	21
Relapsing Polychondritis	NCT06873100	Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis	recruiting	PHASE1/PHASE2	30
Rheumatic Disease	NCT07138898	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	not yet recruiting	PHASE2	80
Rheumatoid Arthritis (RA	NCT06630715	Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.	recruiting	N/A	178
Rhumatoid Arthisis	NCT06687551	JAK Inhibitor Dose TAPering Strategy Study	not yet recruiting	PHASE4	308
Safety Issues	NCT06498167	Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)	recruiting	N/A	150
Sleep Disturbance	NCT06390722	A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis	withdrawn	PHASE3	0
Spondylarthritis	NCT05080218	COVID-19 VaccinE Response in Rheumatology Patients	completed	PHASE4	841
Spondyloarthritis	NCT04169373	A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis	completed	PHASE3	734
Active Anal Fistula	NCT06902987	Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease	recruiting	PHASE1	27
Systemic Lupus Erythematosus	NCT05843643	Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus	active not recruiting	PHASE3	1,014
Takayasu Arteritis (TAK)	NCT04161898	A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)	active not recruiting	PHASE3	56
UC - Ulcerative Colitis	NCT07502339	Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis	not yet recruiting	PHASE4	50
Spondyloarthritis, Axial	NCT06454188	A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis	recruiting	PHASE4	100
Adverse Drug Event	NCT06498167	Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)	recruiting	N/A	150
Adverse Drug Reaction	NCT06498167	Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)	recruiting	N/A	150
Ankylosing Spondylitis (AS)	NCT03178487	A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis	completed	PHASE2	187
Arthritis, Rheumatoid	NCT06016517	Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis	not yet recruiting	N/A	18
Atopic Dermatitis (Eczema)	NCT07448363	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	not yet recruiting	N/A	50
Atopic Dermatitis / Eczema	NCT07448363	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	not yet recruiting	N/A	50
Atopic Dermatitis Patients	NCT07448363	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	not yet recruiting	N/A	50
Atopic Dermatitis, Unspecified	NCT07448363	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	not yet recruiting	N/A	50
Axial Spondylarthritis (axSpA)	NCT07018206	Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis	not yet recruiting	PHASE4	200
Axial Spondylarthritis (r-axSpA)	NCT05094128	A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting	active not recruiting	N/A	338
Behcet Syndrome	NCT07080346	Upadacitinib for Refractory Behcet's Syndrome	completed	PHASE2	27
Biomarker	NCT05121298	Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate	unknown	PHASE3	155
Colitis, Ulcerative	NCT06660693	Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis	recruiting	PHASE3	134
Crohn Disease (CD)	NCT07510191	TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response	recruiting	PHASE4	312
Crohn's Disease (CD)	NCT06922331	Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis	completed	N/A	21

All Upadacitinib Clinical Trials (103)

NCT ID	Title	Status	Phase	Enrollment	Sponsor
NCT07502339	Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis	not yet recruiting	PHASE4	50	University of California, San Francisco
NCT07492251	Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Randomized Placebo-controlled Study.	not yet recruiting	PHASE2	56	Centre Hospitalier Universitaire de Nice
NCT07018206	Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis	not yet recruiting	PHASE4	200	CARE ARTHRITIS LTD.
NCT07448363	Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica	not yet recruiting	N/A	50	Caja Costarricense de Seguro Social
NCT06016517	Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis	not yet recruiting	N/A	18	Tufts Medical Center
NCT07550673	Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）	recruiting	PHASE4	226	Xijing Hospital of Digestive Diseases
NCT07546097	Comparative Effectiveness of Upadacitinib vs Corticosteroids as First-Line Therapy for Acute Severe Ulcerative Colitis（UPFRONT）	recruiting	PHASE4	46	Yongquan Shi
NCT07510191	TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response	recruiting	PHASE4	312	Sixth Affiliated Hospital, Sun Yat-sen University
NCT07425899	A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants	recruiting	PHASE1	32	AbbVie
NCT07258771	Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis	recruiting	PHASE4	110	Berinstein, Jeffrey
NCT07487311	A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)	recruiting	N/A	80	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	not yet recruiting	PHASE4	10	University of California, San Francisco
NCT07138898	Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty	not yet recruiting	PHASE2	80	NYU Langone Health
NCT06928272	Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study	recruiting	PHASE3	348	Douglas D. Fraser
NCT07149467	Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study	not yet recruiting	PHASE3	454	Sixth Affiliated Hospital, Sun Yat-sen University
NCT07064889	The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia	not yet recruiting	PHASE2	132	Peking University People's Hospital
NCT07023302	A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata	recruiting	PHASE3	123	AbbVie
NCT07008846	Efficacy of Tofacitinib, Methotrexate Combination Therapy Versus Upadacitinib, Methotrexate Combination Therapy in Moderate to Severe Rheumatoid Arthritis	active not recruiting	PHASE3	96	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
NCT06660693	Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis	recruiting	PHASE3	134	McMaster University
NCT06862284	Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome	not yet recruiting	PHASE2	30	Peking University People's Hospital
NCT06227910	A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease	recruiting	PHASE3	396	Takeda
NCT06687551	JAK Inhibitor Dose TAPering Strategy Study	not yet recruiting	PHASE4	308	University Hospital, Toulouse
NCT06684522	Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis	recruiting	EARLY_PHASE1	10	Northwestern University
NCT06701331	Safety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis	active not recruiting	PHASE3	99	AbbVie
NCT06454461	Efficacy of Upadacitinib After NECS in Vitiligo	recruiting	NA	60	Jilin University
NCT06454188	A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis	recruiting	PHASE4	100	CARE ARTHRITIS LTD.
NCT06873100	Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis	recruiting	PHASE1/PHASE2	30	Peking University People's Hospital
NCT06461897	A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis	recruiting	PHASE3	675	AbbVie
NCT06332534	Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease	recruiting	PHASE3	110	AbbVie
NCT06573593	Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study	recruiting	N/A	150	Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT06630715	Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.	recruiting	N/A	178	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
NCT06520397	Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's Disease	recruiting	PHASE4	214	Sixth Affiliated Hospital, Sun Yat-sen University
NCT06498167	Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)	recruiting	N/A	150	Universidade do Porto
NCT06389136	A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab	recruiting	PHASE3	200	AbbVie
NCT06390722	A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis	withdrawn	PHASE3	0	AbbVie
NCT06773403	Upadacitinib for Prurigo Nodularis	terminated	PHASE4	5	Psoriasis Treatment Center of Central New Jersey
NCT06379958	Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects	recruiting	PHASE1	48	Modern Biosciences Ltd
NCT07080346	Upadacitinib for Refractory Behcet's Syndrome	completed	PHASE2	27	Liu Tian
NCT06902987	Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease	recruiting	PHASE1	27	Sixth Affiliated Hospital, Sun Yat-sen University
NCT06780683	Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease	recruiting	N/A	174	Xiang Gao
NCT06144567	Response to Upadacitinib of Enthesitis Evaluated by Ultrasound in Patients With Psoriatic Arthritis	not yet recruiting	N/A	19	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
NCT06118411	A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo	active not recruiting	PHASE3	614	AbbVie
NCT05782907	Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.	active not recruiting	PHASE3	122	AbbVie
NCT06095596	Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis	recruiting	NA	334	Sixth Affiliated Hospital, Sun Yat-sen University
NCT06012240	A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata	recruiting	PHASE3	1,500	AbbVie
NCT05609630	Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.	recruiting	PHASE3	90	AbbVie
NCT05867329	Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis	recruiting	PHASE4	162	Berinstein, Jeffrey
NCT05843643	Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus	active not recruiting	PHASE3	1,014	AbbVie
NCT05889182	A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy	recruiting	PHASE3	1,328	AbbVie
NCT05814627	Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis	active not recruiting	PHASE3	487	AbbVie
NCT07472309	Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis	completed	N/A	81	Xijing Hospital of Digestive Diseases
NCT05507580	A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis	completed	PHASE4	461	AbbVie
NCT06758947	Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	completed	PHASE3	60	Assiut University
NCT07442045	Real-World Effectiveness and Safety of Upadacitinib Plus Vedolizumab vs Upadacitinib Monotherapy During Induction in Moderate-to-Severe Ulcerative Colitis	recruiting	N/A	150	Sixth Affiliated Hospital, Sun Yat-sen University
NCT06922331	Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis	completed	N/A	21	Sixth Affiliated Hospital, Sun Yat-sen University
NCT05601882	A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	completed	PHASE3	920	AbbVie
NCT05153200	Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.	unknown	PHASE4	40	Ottawa Hospital Research Institute
NCT05094128	A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting	active not recruiting	N/A	338	AbbVie
NCT05080218	COVID-19 VaccinE Response in Rheumatology Patients	completed	PHASE4	841	Jeffrey Curtis
NCT06937788	Replication of the Heads Up Atopic Dermatitis Trial With Registry Data	recruiting	N/A	240	Technische Universität Dresden
NCT04927975	Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo	completed	PHASE2	185	AbbVie
NCT05121298	Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate	unknown	PHASE3	155	Atsushi Kawakami
NCT04530305	Microbiota Analysis to Predict Outcomes of Rheumatoid Arthritis Patients Treated With JAK-inhibitor	unknown	N/A	60	University Hospital, Montpellier
NCT06274996	Efficacy and Safety Analysis of Upadacitinib in Inflammatory Bowel Disease	completed	N/A	81	Sixth Affiliated Hospital, Sun Yat-sen University
NCT04666675	A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil	withdrawn	PHASE3	0	AbbVie
NCT04451772	A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State	completed	PHASE2	185	AbbVie
NCT04430855	A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms	completed	PHASE2	68	AbbVie
NCT04161898	A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)	active not recruiting	PHASE3	56	AbbVie
NCT04195698	Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis	completed	PHASE3	475	AbbVie
NCT04169373	A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis	completed	PHASE3	734	AbbVie
NCT03978520	A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)	completed	PHASE2	341	AbbVie
NCT03725007	A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis	active not recruiting	PHASE1	124	AbbVie
NCT03823378	A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib	terminated	PHASE2	97	AbbVie
NCT03738397	A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis	completed	PHASE3	673	AbbVie
NCT03646604	A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis	completed	PHASE1	35	AbbVie
NCT03725202	A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis	completed	PHASE3	429	AbbVie
NCT03653026	A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis	completed	PHASE3	522	AbbVie
NCT03661138	A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	completed	PHASE3	272	AbbVie
NCT03682705	A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis	completed	PHASE2	242	AbbVie
NCT03569293	Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)	completed	PHASE3	912	AbbVie
NCT03568318	A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis	active not recruiting	PHASE3	1,533	AbbVie
NCT03607422	A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)	completed	PHASE3	912	AbbVie
NCT03345823	A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433	active not recruiting	PHASE3	747	AbbVie
NCT02955212	A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)	completed	PHASE3	338	AbbVie
NCT03345849	A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies	completed	PHASE3	526	AbbVie
NCT03345836	A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy	completed	PHASE3	624	AbbVie
NCT03178487	A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis	completed	PHASE2	187	AbbVie
NCT03086343	A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs	completed	PHASE3	657	AbbVie
NCT03104374	A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug	completed	PHASE3	642	AbbVie
NCT03104400	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)	completed	PHASE3	1,705	AbbVie
NCT03006068	A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)	active not recruiting	PHASE3	950	AbbVie
NCT03358693	Molecular Signatures in Inflammatory Skin Disease	recruiting	N/A	300	Prof. Dr. Stephan Weidinger
NCT02925117	A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis	completed	PHASE2	167	AbbVie
NCT02819635	A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)	completed	PHASE2/PHASE3	1,302	AbbVie
NCT02706951	A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)	completed	PHASE3	648	AbbVie
NCT02720523	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs	completed	PHASE2/PHASE3	197	AbbVie
NCT02706847	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs	completed	PHASE3	499	AbbVie
NCT02706873	A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate	completed	PHASE3	1,002	AbbVie
NCT02675426	A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone	completed	PHASE3	661	AbbVie
NCT02629159	A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate	active not recruiting	PHASE3	1,629	AbbVie
NCT02066389	A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone	completed	PHASE2	300	AbbVie
NCT02049138	An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis	completed	PHASE2	493	AbbVie
NCT04159597	Expanded Access to Upadacitinib	available	N/A	0	AbbVie

Where to Participate: All Upadacitinib Trial Sites in the U.S. (225 sites across 38 states)

Every actively recruiting Upadacitinibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Cahaba Dermatology & Skin Health Center /ID# 254876	Birmingham35244	NCT05889182	Map
AL	Cahaba Dermatology & Skin Health Center /ID# 263855	Birmingham35244	NCT06389136	Map
AZ	Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272564	Fountain Hills85268	NCT05889182	Map
AZ	Medical Dermatology Specialists /ID# 254226	Phoenix85006	NCT05889182	Map
AZ	Phoenix Children's Hospital /ID# 253403	Phoenix85016-7710	NCT05609630	Map
AZ	Mayo Clinic - Scottsdale /ID# 254388	Scottsdale85259-5452	NCT05889182	Map
AZ	One Of A Kind Clinical Research Center - Scottsdale /ID# 278675	Scottsdale85253	NCT06389136	Map
AZ	Banner University Medicine Dermatology /ID# 255853	Tucson85718-1407	NCT05889182	Map
AR	Clinical Trials Institute - Northwest Arkansas /ID# 254924	Fayetteville72703	NCT05889182	Map
AR	Clinical Trials Institute - Northwest Arkansas /ID# 267290	Fayetteville72703	NCT06389136	Map
AR	Burke Pharmaceutical Research /ID# 254238	Hot Springs71913-6404	NCT05889182	Map
AR	Applied Research Center Of Arkansas /ID# 268547	Little Rock72205	NCT06461897	Map
AR	Arkansas Research Trials /ID# 254233	North Little Rock72217	NCT05889182	Map
AR	NW Arkansas Clinical Trials Center /ID# 254311	Rogers72758	NCT05889182	Map
CA	Private Practice - Dr. Tooraj Raoof /ID# 254374	Encino91436	NCT05889182	Map
CA	Private Practice - Dr. Tooraj Raoof /ID# 263849	Encino91436	NCT06389136	Map
CA	First OC Dermatology /ID# 259220	Fountain Valley92708	NCT06012240	Map
CA	First OC Dermatology /ID# 263349	Fountain Valley92708	NCT06389136	Map
CA	NorCal Medical Research /ID# 278397	Greenbrae94904	NCT06389136	Map
CA	Marvel Clinical Research /ID# 276228	Huntington Beach92647	NCT05889182	Map
CA	Dermatology Research Associates /ID# 254846	Los Angeles90045	NCT05889182	Map
CA	Dermatology Research Associates /ID# 258033	Los Angeles90045	NCT06012240	Map
CA	Allergy & Asthma Associates of Southern California - Mission Viejo /ID# 266574	Mission Viejo92691	NCT06389136	Map
CA	UCSF Benioff Children's Hospital - Oakland /ID# 262217	Oakland94609	NCT06332534	Map
CA	Dermatologist Medical Group of North County- Profound Research /ID# 266512	Oceanside92056	NCT06389136	Map
CA	Lucile Packard Children's Hospital /ID# 262193	Palo Alto94304	NCT06332534	Map
CA	Stanford University School of Medicine - Palo Alto /ID# 269622	Palo Alto94304	NCT06461897	Map
CA	Comprehensive Dermatology Center of Pasadena /ID# 281014	Pasadena91105	NCT06389136	Map
CA	Stanford University School of Medicine - Redwood City /ID# 263776	Redwood City94063	NCT06389136	Map
CA	NorCal Clinical Research /ID# 274219	Rocklin95765	NCT05889182	Map
CA	Integrative Skin Science and Research /ID# 254930	Sacramento95815	NCT05889182	Map
CA	Integrative Skin Science and Research /ID# 258114	Sacramento95815	NCT06012240	Map
CA	Integrative Skin Science and Research /ID# 264537	Sacramento95815	NCT06389136	Map
CA	Integrative Skin Science and Research /ID# 265108	Sacramento95815	NCT06461897	Map
CA	University of California Davis Health /ID# 254229	Sacramento95817	NCT05889182	Map
CA	University of California Davis Health /ID# 258112	Sacramento95817	NCT06012240	Map
CA	Laura Rodriguez Research Institute	San Diego92101	NCT06928272	Map
CA	West Dermatology La Jolla /ID# 265014	San Diego92121	NCT06389136	Map
CA	Clinical Trials Research Institute /ID# 254466	Thousand Oaks91320-2130	NCT05889182	Map
CA	Clinical Trials Research Institute /ID# 258021	Thousand Oaks91320-2130	NCT06012240	Map
CA	Clinical Trials Research Institute /ID# 263846	Thousand Oaks91320	NCT06389136	Map
CO	Children's Hospital Colorado - Aurora /ID# 262207	Aurora80045	NCT06332534	Map
CO	Peak Gastroenterology Associates	Colorado Springs80907	NCT06227910	Map
CT	UConn Health Main /ID# 254507	Farmington06032	NCT05889182	Map
CT	Connecticut Children's Medical Center - Hartford /ID# 262256	Hartford06106	NCT06332534	Map
CT	Yale University School of Medicine /ID# 254586	New Haven06510	NCT05889182	Map
CT	Yale University School of Medicine /ID# 263836	New Haven06510	NCT06389136	Map
DC	Childrens National Medical Center /ID# 253344	Washington D.C.20010-2916	NCT05609630	Map
FL	Skin Care Research Boca Raton /ID# 253814	Boca Raton33486-2269	NCT05889182	Map
FL	Skin Care Research Boca Raton /ID# 258012	Boca Raton33486-2269	NCT06012240	Map
FL	Skin Care Research Boca Raton /ID# 263733	Boca Raton33486-2269	NCT06389136	Map
FL	Apex Clinical Trials /ID# 255756	Brandon33511	NCT05889182	Map
FL	TrueBlue Clinical Research - Brandon /ID# 265037	Brandon33511	NCT06389136	Map
FL	Florida Academic Dermatology Center /ID# 254011	Coral Gables33134-5755	NCT05889182	Map
FL	Pediatric Skin Research /ID# 266308	Coral Gables33146	NCT06461897	Map
FL	Life Clinical Trials - Coral Springs /ID# 267195	Coral Springs33071	NCT06389136	Map
FL	Dermatology Associates of the Palm Beaches /ID# 275950	Delray Beach33445	NCT05889182	Map
FL	FXM Clinical Research Ft. Lauderdale /ID# 280911	Fort Lauderdale33308	NCT06389136	Map
FL	Skin Care Research - Hollywood /ID# 254508	Hollywood33021-6748	NCT05889182	Map
FL	Skin Care Research - Hollywood /ID# 259210	Hollywood33021-6748	NCT06012240	Map
FL	Skin Care Research - Hollywood /ID# 263739	Hollywood33021-6748	NCT06389136	Map
FL	GSI Clinical Research, LLC /ID# 259352	Margate33063	NCT06012240	Map
FL	GSI Clinical Research, LLC /ID# 263760	Margate33063-7011	NCT06389136	Map
FL	Life Clinical Trials /ID# 258613	Margate33063	NCT05889182	Map
FL	FAX Pharma Clinical Research /ID# 280915	Miami33146	NCT06389136	Map
FL	International Dermatology Research /ID# 264961	Miami33144	NCT06389136	Map
FL	Lenus Research and Medical Group /ID# 259356	Miami33172	NCT06012240	Map
FL	Lenus Research and Medical Group /ID# 263779	Miami33172	NCT06389136	Map
FL	Research Associates of South Florida /ID# 267291	Miami33134	NCT06389136	Map
FL	Sullivan Dermatology /ID# 263537	Miami33162	NCT06389136	Map
FL	Fxm Clinical Research - Miramar /ID# 280934	Miramar33027	NCT06389136	Map
FL	Global Clinical Professionals (GCP) /ID# 266474	St. Petersburg33705	NCT06389136	Map
FL	Advanced Clinical Research Institute - Tampa /ID# 259204	Tampa33607	NCT06012240	Map
FL	Advanced Clinical Research Institute /ID# 253746	Tampa33607	NCT05889182	Map
FL	Alliance Clinical Research of Tampa /ID# 264531	Tampa33615	NCT06389136	Map
FL	Skin Care Research - Tampa /ID# 256440	Tampa33607-6438	NCT05889182	Map
FL	Skin Care Research - Tampa /ID# 263750	Tampa33607-6438	NCT06389136	Map
FL	Encore Medical Research - Weston /ID# 278491	Weston33331	NCT06389136	Map
GA	Centricity Research /ID# 255470	Columbus31904-2954	NCT05889182	Map
GA	Centricity Research Columbus Dermatology /ID# 266529	Columbus31904	NCT06389136	Map
GA	Cleaver Medical Group Dermatology /ID# 263788	Dawsonville30534	NCT06389136	Map
GA	Aeroallergy Research Laboratory /ID# 267247	Savannah31406	NCT06461897	Map
ID	Treasure Valley Medical Research /ID# 255208	Boise83706	NCT05889182	Map
ID	Treasure Valley Medical Research /ID# 263738	Boise83706	NCT06389136	Map
ID	Treasure Valley Medical Research /ID# 266838	Boise83706	NCT06461897	Map
IL	DeNova Research /ID# 254372	Chicago60610	NCT05889182	Map
IL	DeNova Research /ID# 264513	Chicago60610	NCT06389136	Map
IL	Northwestern University Department of Dermatology	Chicago60611	NCT06684522	Map
IL	Northwestern University Feinberg School of Medicine /ID# 254503	Chicago60611-2927	NCT05889182	Map
IL	Northwestern University Feinberg School of Medicine /ID# 264983	Chicago60611-2927	NCT06389136	Map
IL	Northwestern University Feinberg School of Medicine /ID# 265117	Chicago60611-2927	NCT06461897	Map
IL	Acpru /Id# 279285	Grayslake60030	NCT07425899	Map
IL	Sneeze Wheeze & Itch Associates /ID# 267238	Normal61761	NCT06461897	Map
IL	OSF St. Francis Medical Center /ID# 262192	Peoria61637-0001	NCT06332534	Map
IL	NorthShore University HealthSystem - Skokie /ID# 254389	Skokie60077	NCT05889182	Map
IN	Dawes Fretzin, LLC /ID# 254390	Indianapolis46256	NCT05889182	Map
IN	Dawes Fretzin, LLC /ID# 265097	Indianapolis46256	NCT06461897	Map
IN	Indiana University Health Riley Hospital for Children /ID# 262215	Indianapolis46202	NCT06332534	Map
IN	Indiana University Health University Hospital /ID# 259827	Indianapolis46202	NCT06012240	Map
IN	Options Research Group /ID# 254537	West Lafayette47906	NCT05889182	Map
IN	Options Research Group /ID# 264564	West Lafayette47906	NCT06389136	Map
KS	U.S. Dermatology Partners Leawood /ID# 255838	Leawood66211-1453	NCT05889182	Map
KY	Equity Medical, LLC /ID# 268270	Bowling Green42104	NCT06461897	Map
KY	Equity Medical, LLC /ID# 271140	Bowling Green42104	NCT05889182	Map
LA	Tulane University School of Medicine /ID# 259799	New Orleans70112	NCT06012240	Map
MD	Maryland Allergy & Asthma Center /ID# 268032	Lanham20706	NCT06461897	Map
MD	DermAssociates - Rockville /ID# 266457	Rockville20850	NCT06461897	Map
MA	Beth Israel Deaconess Medical Center /ID# 253811	Boston02215-5400	NCT05889182	Map
MA	Boston Children's Hospital /ID# 262191	Boston02115	NCT06332534	Map
MA	Boston Specialists /ID# 265810	Boston02111-1901	NCT06389136	Map
MA	Massachusetts General Hospital /ID# 261093	Boston02114	NCT05889182	Map
MA	Beacon Clinical Research /ID# 263843	Quincy02169	NCT06389136	Map
MA	Beacon Clinical Research, LLC /ID# 254419	Quincy02169	NCT05889182	Map
MA	UMass Memorial Medical Center /ID# 258839	Worcester01605	NCT05889182	Map
MI	University of Michigan	Ann Arbor48109	NCT05867329	Map
MI	University of Michigan	Ann Arbor48109	NCT07258771	Map
MI	The Derm Institute Of West Michigan /ID# 275948	Caledonia49316	NCT05889182	Map
MI	Hamzavi Dermatology - Canton /ID# 275856	Canton48187	NCT05889182	Map
MI	Clarkston Dermatology /ID# 258018	Clarkston48346	NCT06012240	Map
MI	Michigan Center for Medical Research /ID# 275860	Clarkston48346	NCT05889182	Map
MI	Henry Ford Medical Center - New Center One /ID# 263522	Detroit48202-3046	NCT06389136	Map
MI	Michigan Dermatology Institute /ID# 254468	Waterford48328	NCT05889182	Map
MN	MNGI Digestive Health, P. A. /ID# 262204	Minneapolis55413-2195	NCT06332534	Map
MO	Cleaver Dermatology /ID# 254391	Kirksville63501-5362	NCT05889182	Map
MO	Dermatology and Skin Center of Lees Summit /ID# 257546	Lee's Summit64064-2301	NCT05889182	Map
MO	MediSearch Clinical Trials /ID# 254392	Saint Joseph64506	NCT05889182	Map
MO	MediSearch Clinical Trials /ID# 263579	Saint Joseph64506	NCT06389136	Map
MO	SSM Health Saint Louis University Hospital /ID# 256437	St Louis63104	NCT05889182	Map
MO	Washington University School of Medicine - St. Louis /ID# 254506	St Louis63130	NCT05889182	Map
MO	Washington University School of Medicine - St. Louis /ID# 268545	St Louis63130	NCT06461897	Map
NE	Physician Research Collaboration, LLC /ID# 263583	Lincoln68516	NCT06389136	Map
NE	Skin Specialists /ID# 259237	Omaha68144	NCT06012240	Map
NE	Skin Specialists /ID# 263345	Omaha68144	NCT06389136	Map
NE	Skin Specialists /ID# 266331	Omaha68144	NCT06461897	Map
NV	Las Vegas Dermatology /ID# 265801	Las Vegas89144	NCT06389136	Map
NV	Las Vegas Dermatology /ID# 272421	Las Vegas89144	NCT05889182	Map
NV	Las Vegas Dermatology /ID# 279317	Las Vegas89144	NCT06012240	Map
NV	Vivida Dermatology- Flamingo /ID# 254227	Las Vegas89119-5190	NCT05889182	Map
NV	Skin Cancer and Dermatology Institute - Reno /ID# 254410	Reno89509	NCT05889182	Map
NV	Skin Cancer and Dermatology Institute - Reno /ID# 259208	Reno89509	NCT06012240	Map
NV	Skin Cancer and Dermatology Institute - Reno /ID# 263771	Reno89509	NCT06389136	Map
NH	Dartmouth Hitchcock Medical Center - Old Etna Road /ID# 263840	Lebanon03766	NCT06389136	Map
NY	Empire Dermatology /ID# 276241	East Syracuse13057	NCT05889182	Map
NY	NorthWell Health - Dermatology /ID# 254704	New Hyde Park11042-2058	NCT05889182	Map
NY	Equity Medical /ID# 266680	New York10023-7340	NCT06012240	Map
NY	Equity Medical, LLC /ID# 265814	New York10023-7340	NCT06389136	Map
NY	Icahn School of Medicine at Mount Sinai /ID# 262216	New York10029	NCT06332534	Map
NY	Private Practice - Dr. Bobby Buka /ID# 276371	New York10012	NCT05889182	Map
NY	Sadick Research Group LLC /ID# 266790	New York10075	NCT06012240	Map
NY	Weill Cornell Medicine /ID# 265793	New York10065	NCT06389136	Map
NY	New York Medical College /ID# 253437	Valhalla10595	NCT05609630	Map
NC	Univ NC Chapel Hill /ID# 262198	Chapel Hill27514-4220	NCT06332534	Map
NC	Onsite Clinical Solutions /ID# 254854	Charlotte28277-3816	NCT05889182	Map
NC	Duke University Medical Center /ID# 256898	Durham27710	NCT05889182	Map
NC	Piedmont Plastic Surgery and Dermatology - Huntersville /ID# 266545	Huntersville28078-7961	NCT06389136	Map
OH	DOCS Clinical Research - Canal Winchester /ID# 268271	Canal Winchester43110-2069	NCT06461897	Map
OH	Apex Clinical Research Center, LLC /ID# 275956	Canton44718	NCT05889182	Map
OH	Cincinnati Childrens Hospital Medical Center /ID# 251827	Cincinnati45229	NCT05609630	Map
OH	Cleveland Clinic - Cleveland /ID# 258113	Cleveland44195	NCT06012240	Map
OH	UH Cleveland Medical Center /ID# 262188	Cleveland44106	NCT06332534	Map
OH	University Hospitals Cleveland Medical Center	Cleveland44106	NCT06454188	Map
OH	ClinOhio Research Services /ID# 254851	Columbus43213-4440	NCT05889182	Map
OH	Wright State Physicians Health Center /ID# 268841	Fairborn45324	NCT06461897	Map
OH	Dermatologists of Southwest Ohio, Inc /ID# 254297	Mason45040-4520	NCT05889182	Map
OH	Dermatologists of Southwest Ohio, Inc /ID# 260116	Mason45040-4520	NCT06012240	Map
OH	Dermatology Partners - Medina /ID# 275939	Medina44256	NCT05889182	Map
OK	Lynn Institute of Oklahoma City /ID# 253791	Oklahoma City73112	NCT05889182	Map
OR	Oregon Dermatology and Research Center /ID# 258243	Portland97210	NCT06012240	Map
OR	Oregon Health and Science University	Portland97239	NCT06454188	Map
OR	Oregon Health and Science University /ID# 254929	Portland97239	NCT05889182	Map
OR	Oregon Health and Science University /ID# 263736	Portland97239	NCT06389136	Map
OR	Oregon Health and Science University /ID# 266483	Portland97239	NCT06461897	Map
OR	Randall Children's Hospital /ID# 251829	Portland97227-1654	NCT05609630	Map
PA	Penn State Milton S. Hershey Medical Center /ID# 254925	Hershey17033-2360	NCT05889182	Map
PA	Children's Hospital of Philadelphia - Main /ID# 262197	Philadelphia19104-4319	NCT06332534	Map
PA	Clinical Research of Philadelphia /ID# 264972	Philadelphia19114	NCT06389136	Map
PA	Clinical Research of Philadelphia, LLC /ID# 255308	Philadelphia19114	NCT05889182	Map
PA	University of Pennsylvania	Philadelphia19104	NCT06454188	Map
PA	University of Pittsburgh Medical Center /ID# 264526	Pittsburgh15213	NCT06389136	Map
PA	Dermatology Associates of Plymouth Meeting /ID# 267286	Plymouth Meeting19462	NCT06389136	Map
SC	Medical University of South Carolina /ID# 263655	Charleston29425	NCT06389136	Map
SC	Medical University of South Carolina /ID# 265113	Charleston29425	NCT06461897	Map
SC	Medical University of South Carolina /ID# 272569	Charleston29425	NCT05889182	Map
SC	Advanced Dermatology And Cosmetic Surgery - Spartanburg /ID# 267185	Spartanburg29307	NCT06389136	Map
SC	Advanced Dermatology And Cosmetic Surgery - Spartanburg /ID# 278359	Spartanburg29307	NCT06012240	Map
SD	Health Concepts /ID# 263383	Rapid City57702	NCT06389136	Map
TN	Dermatology Associates of Knoxville /ID# 261082	Knoxville37917	NCT05889182	Map
TN	International Clinical Research - Tennessee LLC /ID# 259552	Murfreesboro37130-2450	NCT06012240	Map
TX	Arlington Research Center, Inc /ID# 253805	Arlington76011	NCT05889182	Map
TX	Arlington Research Center, Inc /ID# 258028	Arlington76011	NCT06012240	Map
TX	Arlington Research Center, Inc /ID# 263665	Arlington76011	NCT06389136	Map
TX	Arlington Research Center, Inc /ID# 266330	Arlington76011	NCT06461897	Map
TX	Bellaire Dermatology Associates /ID# 253797	Bellaire77401	NCT05889182	Map
TX	Bellaire Dermatology Associates /ID# 259360	Bellaire77401	NCT06012240	Map
TX	U.S. Dermatology Partners - Cedar Park /ID# 259367	Cedar Park78613	NCT06012240	Map
TX	Studies in Dermatology LLC /ID# 263335	Cypress77429	NCT06389136	Map
TX	Dermatology Treatment and Research Center /ID# 259357	Dallas75230	NCT06012240	Map
TX	Dermatology Treatment and Research Center /ID# 265812	Dallas75230	NCT06389136	Map
TX	HRMD Research Dallas /ID# 255256	Dallas75240-6246	NCT05889182	Map
TX	Modern Research Associates /ID# 263852	Dallas75231	NCT06389136	Map
TX	Modern Research Associates, PLLC /ID# 253810	Dallas75231	NCT05889182	Map
TX	3A Research - East location /ID# 267622	El Paso79925	NCT06461897	Map
TX	BRCR Global - Katy /ID# 267304	Katy77450	NCT06389136	Map
TX	Prime Clinical Research - Mansfield - East Broad Street /ID# 268042	Mansfield76063	NCT06461897	Map
TX	Sms Clinical Research /ID# 278676	Mesquite75149	NCT06389136	Map
TX	Texas Dermatology Research Center, LLC /ID# 254928	Plano75025	NCT05889182	Map
TX	Progressive Clinical Research - San Antonio /ID# 267262	San Antonio78229	NCT06461897	Map
TX	Southern Star Research Institute, LLC	San Antonio78229	NCT06227910	Map
TX	Texas Dermatology and Laser Specialists /ID# 267249	San Antonio78218	NCT06461897	Map
TX	Stride Clinical Research /ID# 267331	Sugar Land77479	NCT06389136	Map
TX	The Woodlands Dermatology Associates /ID# 266547	The Woodlands77380	NCT06389136	Map
TX	Dermatology Associates of Tyler /ID# 264980	Tyler75703	NCT06389136	Map
TX	Tyler Research Institute, LLC	Tyler75701	NCT06227910	Map
TX	Center for Clinical Studies Webster TX /ID# 254242	Webster77598	NCT05889182	Map
UT	Cope Family Medicine - Ogden Clinic /ID# 276227	Bountiful84010	NCT05889182	Map
UT	University of Utah /ID# 254452	Murray84107	NCT05889182	Map
UT	Jordan Valley Dermatology & Research Center /ID# 267092	South Jordan84095	NCT06461897	Map
UT	Springville Dermatology - Springville /ID# 276225	Springville84663	NCT05889182	Map
VA	University of Virginia - Dermatology /ID# 254535	Charlottesville22903	NCT05889182	Map
VA	The Education & Research Foundation, Inc. /ID# 254852	Lynchburg24501-1403	NCT05889182	Map
VA	Virginia Clinical Research /ID# 254538	Norfolk23507	NCT05889182	Map
WA	Frontier Dermatology /ID# 254554	Mill Creek98012	NCT05889182	Map
WV	West Virginia Research Institute - Morgantown /ID# 264930	Morgantown26505	NCT06389136	Map
WV	West Virginia University Hospitals /ID# 265114	Morgantown26506	NCT06461897	Map
WI	Wisconsin Medical Center /ID# 267236	Milwaukee53226	NCT06461897	Map

Browse Upadacitinib Trials by State

New York clinical trials Florida clinical trials Texas clinical trials Oregon clinical trials Illinois clinical trials Indiana clinical trials Massachusetts clinical trials California clinical trials Pennsylvania clinical trials South Carolina clinical trials

upadacitinibatopic dermatitisrheumatoid arthritisulcerative colitis (uc)crohn's diseasepsoriatic arthritisclinical trials

Data sourced from the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI). Report generated June 2, 2026.

Recent Upadacitinib updates

What Is Upadacitinib?

Uses and Conditions Under Study

Dosing

Side Effects

Clinical Trial Results

Currently Recruiting Trials

Where to Participate

Development Timeline

Upadacitinib Development Timeline

Conditions Under Study

All Upadacitinib Clinical Trials (103)

Sponsors

Where to Participate: All Upadacitinib Trial Sites in the U.S. (225 sites across 38 states)

Browse Upadacitinib Trials by State